Boston Scientific Other accrued liabilities increased by 0.5% to $840.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.8%, from $701.00M to $840.00M. Over 4 years (FY 2020 to FY 2024), Other accrued liabilities shows an upward trend with a 3.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A sudden increase may indicate rising operational overhead or pending settlements, while stability suggests predictable expense management.
This captures miscellaneous short-term obligations that do not fall into specific categories like accounts payable or ac...
Standard across all capital-intensive industries as a residual category for miscellaneous payables.
other_other_accrued_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $612.00M | $574.00M | $686.00M | $601.00M | $615.00M | $596.00M | $674.00M | $620.00M | $653.00M | $619.00M | $696.00M | $639.00M | $667.00M | $701.00M | $751.00M | $657.00M | $836.00M | $840.00M |
| QoQ Change | — | -6.2% | +19.5% | -12.4% | +2.3% | -3.1% | +13.1% | -8.0% | +5.3% | -5.2% | +12.4% | -8.2% | +4.4% | +5.1% | +7.1% | -12.5% | +27.2% | +0.5% |
| YoY Change | — | — | — | — | +0.5% | +3.8% | -1.7% | +3.2% | +6.2% | +3.9% | +3.3% | +3.1% | +2.1% | +13.2% | +7.9% | +2.8% | +25.3% | +19.8% |